ReviewFuture cardiology2025
Atrial cardiomyopathy: current clinical perspectives and future insights.
Review in Future cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Predictive accuracy of left atrial strain parameters for risk of atrial fibrillation recurrence: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Atrial Cardiomyopathy: Pathophysiology, Diagnostic Approaches, and Prognostic Implications-A Narrative Review.Journal of clinical medicine · 2026Review
- Left atrial strain parameters for predicting new-onset atrial fibrillation: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2026Review
- Stroke in Dilated Cardiomyopathy: An Autopsy-Based Study of Mechanisms, Topography, and Clinical Implications.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial cardiomyopathy (ACM) is an underrecognized cardiac entity marked by structural, contractile, or electrophysiological changes in the atria, yet it lacks established clinical diagnostic criteria and management guidelines. These alterations - driven by molecular, mechanical, and genetic factors - lead to atrial remodeling and contribute to arrhythmogenesis, thromboembolic complications, and the progression of heart failure. Despite recent advances in imaging, biomarkers, and histopathological classifications, the pathophysiology of ACM remains complex and multifactorial, involving processes such as inflammation, oxidative stress, and genetic predisposition. This review synthesizes current knowledge on ACM, including its classification, pathophysiologic mechanisms, and clinical relevance in atrial fibrillation, ischemic stroke, and heart failure with preserved ejection fraction (HFpEF). We also explore emerging diagnostic tools and biomarkers that may aid in risk stratification and therapeutic decision-making. Ultimately, we aim to underscore the clinical significance of ACM and advocate for the development of standardized diagnostic frameworks and personalized treatment strategies to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.